ICCC Past Earnings Q&A
What was the best and worst ICCC past earnings results?
For ImmuCell, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?
The highest ICCC past earnings result in our data set was 0.15/share posted in Q1 2015, while the lowest was in Q1 2023 when ICCC posted -0.300/share.
The biggest top line earnings performance — aka revenue — quarter was in Q1 2022 when ICCC reported 0.01B in revenue, while the quarter with the lowest revenue in our data set was Q2 2014 at 1.54M of revenue.
There are 39 ICCC past earnings results in our data set.
On this page we presented the ICCC past earnings date information for ImmuCell. Reviewing that
ICCC Past Earnings
for the company, we see that the highest past earnings result in our data set was in Q1 2015, when ICCC posted gaap of 0.15/share. Meanwhile the lowest ICCC past earnings result was in Q1 2023, when ICCC posted gaap of -0.300/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q1 2022 when ICCC reported 0.01B in revenue, while the smallest revenue quarter was Q2 2014 when ICCC reported 1.54M in revenue.
Any self directed investor doing their due diligence on ICCC or any other given stock can benefit from
researching all of the ImmuCell past earnings — and here, we present each quarter's result all together
on one page for easy comparison. Studying this information can help when projecting future earnings, as well
as determining whether the past earnings trajectory justifies the current stock value.
That's why we bring you PastEarnings
.com to make it easy for investors to investigate
ImmuCell past earnings, or the past earnings information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for ICCC. Thanks for visiting, and the next
time you need to research ICCC past earnings
or those of another stock, we hope you'll think of our site, as your
go-to past earnings research resource of choice.